NO20052912L - Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil - Google Patents

Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil

Info

Publication number
NO20052912L
NO20052912L NO20052912A NO20052912A NO20052912L NO 20052912 L NO20052912 L NO 20052912L NO 20052912 A NO20052912 A NO 20052912A NO 20052912 A NO20052912 A NO 20052912A NO 20052912 L NO20052912 L NO 20052912L
Authority
NO
Norway
Prior art keywords
modafinil
optical enantiomers
crystalline forms
preparing crystalline
crystalline
Prior art date
Application number
NO20052912A
Other languages
English (en)
Other versions
NO20052912D0 (no
NO335724B1 (no
Inventor
Gerard Coquerel
Adriaan Jan Van Langevelde
Laurent Courvoisier
Stephanie Graf
Gilles Serrure
Olivier Neckerbrock
Sebastien Rose
Christine Besselievre
Original Assignee
Organisation De Synthese Monof
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32406320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052912(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organisation De Synthese Monof filed Critical Organisation De Synthese Monof
Publication of NO20052912D0 publication Critical patent/NO20052912D0/no
Publication of NO20052912L publication Critical patent/NO20052912L/no
Publication of NO335724B1 publication Critical patent/NO335724B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører en fremgangsmåte for fremstilling av krystallinske former av de optiske enantiomerer av modafinil, omfattende de følgende trinn: i) oppløsning av en av de optiske enantiomerer av modafinil i et annet løsningsmiddel enn etanol, ii) modafinilenantiomeren krystalliseres, iii) den krystallinske form av modafinilenantiomeren oppnådd på denne måte utvinnes. Oppfinnelsen vedrører o gså en fremgangsmåte for fremstilling av de optiske enantiomerer av modafinil.
NO20052912A 2002-12-20 2005-06-15 Krystallinske former av optiske enantiomerer av modafinil, farmasøytiske blandinger omfattende slike, fremgangsmåte for fremstilling av slike samt deres anvendelse NO335724B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0216412A FR2849029B1 (fr) 2002-12-20 2002-12-20 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
PCT/FR2003/003799 WO2004060858A1 (fr) 2002-12-20 2003-12-18 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil

Publications (3)

Publication Number Publication Date
NO20052912D0 NO20052912D0 (no) 2005-06-15
NO20052912L true NO20052912L (no) 2005-07-19
NO335724B1 NO335724B1 (no) 2015-02-02

Family

ID=32406320

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052912A NO335724B1 (no) 2002-12-20 2005-06-15 Krystallinske former av optiske enantiomerer av modafinil, farmasøytiske blandinger omfattende slike, fremgangsmåte for fremstilling av slike samt deres anvendelse

Country Status (30)

Country Link
US (10) US7132570B2 (no)
EP (6) EP2343275B1 (no)
JP (2) JP4719471B2 (no)
KR (1) KR101050565B1 (no)
CN (5) CN101654423A (no)
AR (1) AR042546A1 (no)
AU (2) AU2003299349C1 (no)
BR (1) BRPI0316916B1 (no)
CA (2) CA2510096C (no)
CL (2) CL2007002450A1 (no)
CY (1) CY1114291T1 (no)
DK (1) DK2343275T3 (no)
EA (1) EA009592B1 (no)
EG (1) EG24849A (no)
ES (3) ES2575018T3 (no)
FR (1) FR2849029B1 (no)
HK (1) HK1225371A1 (no)
IL (1) IL169205A (no)
IS (1) IS7947A (no)
MX (1) MXPA05006525A (no)
MY (1) MY142926A (no)
NO (1) NO335724B1 (no)
NZ (2) NZ540733A (no)
PL (1) PL377196A1 (no)
PT (1) PT2343275E (no)
SI (1) SI2343275T1 (no)
TW (1) TWI344952B (no)
UA (1) UA100964C2 (no)
WO (1) WO2004060858A1 (no)
ZA (1) ZA200504805B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077894A1 (en) * 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US7521553B2 (en) 2003-03-17 2009-04-21 Hetero Drugs Limited Crystalline forms of lamotrigine
DK1610796T3 (da) * 2003-03-17 2014-07-21 Neurohealing Pharmaceuticals Inc Højpotent dopaminerg behandling af neurologisk svækkelse, som er forbundet med hjerneskade
JP4842819B2 (ja) * 2003-09-04 2011-12-21 セフアロン・インコーポレーテツド モダフィニル組成物
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1516869A1 (en) 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー ［Ｒ−（Ｒ＊，Ｒ＊）］−２−（４−フルオロフェニル）−β、δ−ジヒドロキシ−５−（１−メチルエチル）−３−フェニル−４−［（フェニルアミノ）カルボニル］−１Ｈ−ピロール−１−ヘプタン酸カルシウム塩（２：１）の新規形態
US20060086667A1 (en) * 2004-09-13 2006-04-27 Cephalon, Inc., U.S. Corporation Methods for the separation of enantiomeric sulfinylacetamides
EP1702915A1 (en) 2005-03-14 2006-09-20 Cephalon France Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
AU2006272874B2 (en) * 2005-07-21 2010-03-11 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
MX2007012605A (es) * 2006-02-21 2008-01-11 Teva Pharma Formas cristalinas novedosas de armodafinil y preparacion de ellas.
CA2634133A1 (en) 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
AU2007272501A1 (en) * 2006-07-12 2008-01-17 Elan Pharma International Limited Nanoparticulate formulations of modafinil
WO2008021341A2 (en) * 2006-08-14 2008-02-21 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US20080214862A1 (en) * 2006-12-06 2008-09-04 Ben-Zion Dolitzky Processes for preparing armodafinil intermediate
US20100010092A1 (en) * 2006-12-19 2010-01-14 Arless Ltd. Use of modafinil to treat restless leg syndrome
US20100234468A1 (en) * 2007-06-04 2010-09-16 Abhay Gaitonde Novel process
WO2009024863A2 (en) * 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
WO2009025791A2 (en) * 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
WO2009045488A2 (en) * 2007-10-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of armodafinil and preparation thereof
WO2009090663A1 (en) * 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2292306B1 (en) 2009-09-02 2013-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device
US20130085304A1 (en) * 2009-11-19 2013-04-04 Ranbaxy Laboratories Limited Processes for preparation of polymorphic forms of lacosamide
CN102781446A (zh) * 2010-01-07 2012-11-14 维瓦斯公司 采用碳酸酐酶抑制剂和另外的活性剂的组合治疗阻塞性睡眠呼吸暂停综合征
EP2649187B1 (en) 2010-12-08 2017-11-22 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
US10466776B2 (en) * 2014-06-24 2019-11-05 Paypal, Inc. Surfacing related content based on user interaction with currently presented content
US10326922B2 (en) * 2014-07-23 2019-06-18 Orcam Technologies Ltd. Wearable apparatus and method for capturing image data using multiple image sensors
CN107000038A (zh) * 2014-11-27 2017-08-01 株式会社Gc 蜡模的表面处理剂以及制造牙科假体的方法
WO2017064723A1 (en) * 2015-10-12 2017-04-20 Natco Pharma Ltd An improved process for the preparation of armodafinil

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
GB1197809A (en) 1968-02-13 1970-07-08 Inst Noguchi Method for Continuous Optical Resolution of Organic Racemates.
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2597864B1 (fr) 1986-04-28 1990-11-16 Lafon Labor Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique
FR2626881B1 (fr) 1988-02-10 1990-07-27 Lafon Labor 1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2671349B1 (fr) 1991-01-09 1993-04-23 Lafon Labor Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
FR2710337B1 (fr) * 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
CN1249932A (zh) 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
EP1248869A2 (en) 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
US20010036640A1 (en) 2000-04-25 2001-11-01 D'amico Kevin L. System and methods for the high throughput screening of polymorphs
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
DE10025756C2 (de) * 2000-05-25 2003-02-20 Cognis Deutschland Gmbh Lösungsvermittler
WO2005077894A1 (en) 2004-02-06 2005-08-25 Cephalon, Inc. Modafinil compositions
ES2277937T3 (es) * 2000-07-27 2007-08-01 Teva Pharmaceutical Industries Ltd. Modafinilo puro y cristalino y su procedimiento de preparacion.
US6835307B2 (en) * 2000-08-04 2004-12-28 Battelle Memorial Institute Thermal water treatment
US6489363B2 (en) 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6919378B2 (en) 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
KR100704213B1 (ko) 2000-11-03 2007-04-10 테바 파마슈티컬 인더스트리즈 리미티드 아토르바스타틴 헤미-칼슘 ｖｉｉ형
US7297346B2 (en) 2001-05-25 2007-11-20 Cephalon Inc. Pharmaceutical formulations of modafinil
US20030119060A1 (en) 2001-08-10 2003-06-26 Desrosiers Peter J. Apparatuses and methods for creating and testing pre-formulations and systems for same
EP1466166B2 (en) 2002-01-15 2013-05-01 Avantium International B.V. Method for performing powder diffraction analysis
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US7229644B2 (en) 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
EP1525049B1 (en) 2002-08-02 2007-07-04 Avantium International B.V. An assembly and method for performing parallel chemical experiments, in particular crystallisation experiments
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
EP1567497B1 (en) 2002-12-06 2009-09-23 Purdue Research Foundation Pyridines for treating injured mammalian nerve tissue
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
NZ545133A (en) 2003-09-04 2009-12-24 Cephalon Inc Modafinil compositions
US7566805B2 (en) * 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
KR100872675B1 (ko) 2004-10-13 2008-12-10 파마시아 앤드 업존 캄파니 엘엘씨 3-[5-클로로-4-[(2,4-디플루오로벤질)옥시]-6-옥소피리미딘-1(6ｈ)-일]-ｎ-(2-히드록시에틸)-4-메틸벤즈아미드의결정형
AU2006272874B2 (en) * 2005-07-21 2010-03-11 Neurohealing Pharmaceuticals, Inc. Rapid onset and short term modafinil compositions and methods of use thereof
MX2007012605A (es) * 2006-02-21 2008-01-11 Teva Pharma Formas cristalinas novedosas de armodafinil y preparacion de ellas.
CA2634133A1 (en) 2006-03-01 2007-09-13 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
US20100234468A1 (en) 2007-06-04 2010-09-16 Abhay Gaitonde Novel process
WO2009024863A2 (en) 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
WO2009025791A2 (en) 2007-08-16 2009-02-26 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
WO2009045488A2 (en) 2007-10-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of armodafinil and preparation thereof
EP1911739A3 (en) * 2007-11-05 2008-09-17 Dipharma Francis S.r.l. Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate
WO2009090663A1 (en) 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof

Also Published As

Publication number Publication date
PT2343275E (pt) 2013-07-30
SI2343275T1 (sl) 2013-10-30
EA200501016A1 (ru) 2005-12-29
US20090281192A1 (en) 2009-11-12
DK2343275T3 (da) 2013-07-01
EP2343275A3 (fr) 2011-08-17
FR2849029B1 (fr) 2005-03-18
KR101050565B1 (ko) 2011-07-19
EG24849A (en) 2010-10-27
BRPI0316916B1 (pt) 2021-11-30
IS7947A (is) 2005-07-19
EP1572635B1 (fr) 2017-04-12
CL2016002640A1 (es) 2017-03-24
US20060135621A1 (en) 2006-06-22
EP2676952A3 (fr) 2014-02-12
TWI344952B (en) 2011-07-11
US8975442B2 (en) 2015-03-10
US8729305B2 (en) 2014-05-20
US9382200B2 (en) 2016-07-05
US20130274521A1 (en) 2013-10-17
ES2425023T3 (es) 2013-10-10
PL377196A1 (pl) 2006-01-23
AU2003299349C1 (en) 2011-01-20
EP2679577A2 (fr) 2014-01-01
US20100048718A1 (en) 2010-02-25
AU2003299349A8 (en) 2004-07-29
HK1192222A1 (zh) 2014-08-15
EP2343275A2 (fr) 2011-07-13
AU2003299349B2 (en) 2010-06-03
CN101914044A (zh) 2010-12-15
EP2679578A2 (fr) 2014-01-01
NO20052912D0 (no) 2005-06-15
CN1751021A (zh) 2006-03-22
CN100540533C (zh) 2009-09-16
EP2679578A3 (fr) 2014-03-19
EP2679576A3 (fr) 2014-02-12
EA009592B1 (ru) 2008-02-28
US7132570B2 (en) 2006-11-07
JP4719471B2 (ja) 2011-07-06
BR0316916A (pt) 2005-10-18
CA2510096A1 (fr) 2004-07-22
NZ571235A (en) 2010-01-29
EP2343275B1 (fr) 2013-04-24
JP2006511588A (ja) 2006-04-06
CN101012189B (zh) 2013-03-13
FR2849029A1 (fr) 2004-06-25
US20100022653A1 (en) 2010-01-28
US20060241320A1 (en) 2006-10-26
AU2003299349A1 (en) 2004-07-29
AU2010212462A1 (en) 2010-09-16
US20090281193A1 (en) 2009-11-12
EP2679578B1 (fr) 2016-03-09
NO335724B1 (no) 2015-02-02
WO2004060858A1 (fr) 2004-07-22
HK1225371A1 (zh) 2017-09-08
US20100048720A1 (en) 2010-02-25
EP2676952A2 (fr) 2013-12-25
EP2679576A2 (fr) 2014-01-01
ES2627808T3 (es) 2017-07-31
IL169205A (en) 2013-11-28
EP1572635A1 (fr) 2005-09-14
CL2007002450A1 (es) 2009-01-16
UA100964C2 (ru) 2013-02-25
MY142926A (en) 2011-01-31
TW200419175A (en) 2004-10-01
CA2510096C (fr) 2011-02-22
US20140031589A1 (en) 2014-01-30
CN101654423A (zh) 2010-02-24
EP2679577A3 (fr) 2014-02-12
CN106065007A (zh) 2016-11-02
JP2011102330A (ja) 2011-05-26
CA2724305A1 (fr) 2004-07-22
CN101012189A (zh) 2007-08-08
CY1114291T1 (el) 2016-08-31
JP5497680B2 (ja) 2014-05-21
US20100048719A1 (en) 2010-02-25
MXPA05006525A (es) 2005-12-05
KR20050085847A (ko) 2005-08-29
ZA200504805B (en) 2006-07-26
NZ540733A (en) 2008-10-31
ES2575018T3 (es) 2016-06-23
BRPI0316916A8 (pt) 2015-09-22
AR042546A1 (es) 2005-06-22

Similar Documents

Publication Publication Date Title
NO20052912L (no) Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil
DE60316688D1 (de) Dehydrophenylahistine und analoge davon sowie ein verfahren zur herstellung von dehydrophenylahistinen und analogen davon
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
ATE423778T1 (de) Verfahren zur herstellung von anthranilsäurederivat-hydrat
NO20054614L (no) Fremgangsmate til fremstilling av 68Ga
ATE417036T1 (de) Verbessertes verfahren zur herstellung von 3- hydroxy-4-hydroxymethyl-pyrrolidin-verbindungen
ATE291006T1 (de) Verfahren zur herstellung von salbutamolisomeren
ATE515496T1 (de) Verfahren zur herstellung von enantiomerenangereicherter indolin-2-carbonsäure
ATE281434T1 (de) Verfahren zur herstellung von benzoperhydroisoindolen
ATE297933T1 (de) Ein verfahren zur herstellung von hochreinem cefpodoxim-proxetil
ATE445601T1 (de) Verfahren zur herstellung von carvedilol und seinen enantiomeren
DE50307171D1 (de) Verfahren zur herstellung von 3-amidinophenylalanin-derivaten
ATE370950T1 (de) Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol
ATE526312T1 (de) Verfahren zur herstellung von reinen 4- pyrrolidinophenylbenzyletherderivaten als maob- inhibitoren
ATE496038T1 (de) Verfahren zur herstellung von quetiapin
ATE318815T1 (de) Verfahren zur herstellung von enantiomeren von indol-2,3-dion-3-oximderivaten
ATE469149T1 (de) Verfahren zur herstellung von cabergolin
BRPI0513881A (pt) processo para a preparação de compostos opticamente ativos
ATE375355T1 (de) Verfahren zur herstellung von cefpodoxim-proxetil
WO2006034812A3 (de) Verfahren zur herstellung von optisch aktiven 2-methylalkan-1-ols aus dem entsprechenden 2-methylalk-2-en-1-al, umfassend eine carbonylselektive reduktion, eine enantioselektive hydrierung und eine lipase-katalysierte, stereoselektive acylierung zwecks anreicherung des gewünschten enatiomers
DE60314904D1 (de) Verfahren zur herstellung von chinoloncarboxylat-derivaten
DE602004006021D1 (de) Verfahren zur racematspaltung von nefopam
ATE549315T1 (de) Verfahren zur herstellung von kristallinem perindopril
MX2007011274A (es) Procesos y metodos para la preparacion de cis-2-hidroximetil-4-(ci tosin-1-il)-1,3-oxatiolano opticamente activas o sales aceptables farmaceuticamente del mismo.
ATE425143T1 (de) Verfahren zur herstellung von indolen

Legal Events

Date Code Title Description
MK1K Patent expired